Trial Profile
A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Bafetinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PROACT
- Sponsors LadRx Corporation
- 14 Dec 2011 Additional lead trial investigator (Daniel Levitt) identified as reported by ClinicalTrials.gov.
- 14 Dec 2011 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.